Understand the source comparison
Selank Amidate for Nootropic Research: Formulation Comparison
The table below compares Selank amidate against standard Selank and related nootropic peptides across key research parameters. Understanding these differences is critical for protocol design. Half-life, receptor targets, and administration routes directly dete
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares Selank amidate against standard Selank and related nootropic peptides across key research parameters. Understanding these differences is critical for protocol design. Half-life, receptor targets, and administration routes directly determine experimental feasibility.
- Selank Amidate
- 3–5 hours
- GABAa allosteric modulation, MAO inhibition, BDNF upregulation
- 100–500 mcg/kg
- Intranasal, subcutaneous
- Extended duration makes once-daily protocols viable; best for sustained anxiolytic and cognitive studies
- Standard Selank
- 0.5–1.0 hours
- GABAa modulation (identical mechanism but shorter duration)
- Requires multiple daily dosing; useful for acute-phase studies but impractical for chronic protocols
- Semax Amidate
- 2–4 hours
- BDNF/NGF upregulation, dopaminergic modulation
- 200–600 mcg/kg
- Focused on neuroplasticity and learning; less anxiolytic effect than Selank amidate
- Cerebrolysin
- 4–6 hours (peptide fractions)
- Neurotrophic factor mimicry, NMDA receptor modulation
- 0.5–2.5 mL/kg
- Intramuscular, intravenous
- Multi-peptide complex; broader neuroprotective profile but less targeted than single-peptide compounds
- Dihexa
- 2–3 hours
- HGF/c-Met receptor agonism, synaptogenesis
- 1–5 mg/kg
- Oral, subcutaneous
- Potent neuroplasticity agent; higher cognitive enhancement ceiling but also higher risk of protocol variability